Skip to main content

Sanofi looks to accelerate MS treatment with $3.68 billion acquisition of Principia Biopharma

Sanofi Chief Executive Paul Hudson strikes his second biotech deal since taking over at the French drugmaker last year.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.